Sanofi’s head of strategy and business development to retire amid company review

pharmafile | November 25, 2019 | News story | Sales and Marketing Bristol Meyers, Gilead, Sanofi, Shell 

One of Sanofi’s most senior strategy bosses is set to retire at the end of the month. Muzammil Mansuri, Executive Vice President of Strategy and Business Development, leaves the company during a strategic review.

Mansuri started out as a research scientist at Shell before moving to Bristol-Meyers. His last role before joining Sanofi in 2016 was the Senior VP of R&D Strategy and Corporate Development at Gilead Sciences.

A spokesperson told Endpoints News that Mansuri had played a key role in Sanofi’s strategic moves over the last four years, overseeing acquisitions and ‘’structuring partnerships and alliances that contributed to the deployment of our strategy and growth’’.  Sanofi said that his retirement was planned.

It is the first management shakeup under new CEO Paul Hudson, who took over on 1 September. Under his leadership the company is carrying out a strategic review due to setbacks experienced under his predecessor. He inherited a company with an R&D department that lags behind the competition, a diabetes arm that is in decline and a slipping stock price. Hudson is expected to unveil the company’s plans for the future at an investor day on 10 December in Cambridge Massachusetts.

Conor Kavanagh

Related Content

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …

Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the …

Janssen and Sanofi enter agreement for potential vaccine programme

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …

Latest content